Results 51 to 60 of about 166,325 (167)

Metabonomics study of the therapeutic mechanism of Gynostemma pentaphyllum and atorvastatin for hyperlipidemia in rats. [PDF]

PLoS ONE, 2013
Gynostemma pentaphyllum (GP) is widely used for the treatment of diseases such as hyperlipidemia, fatty liver and obesity in China, and atorvastatin is broadly used as an anti-hyperlipidemia drug. This research focuses on the plasma and liver metabolites
Miao Wang, Fei Wang, Yinan Wang, Xiaonan Ma, Min Zhao, Chunjie Zhao   +5 more
doaj   +1 more source

Treatment of Hyperlipidemia.

Internal Medicine, 2000
In the treatment of hyperlipidemia, when to begin and end therapy is important. In recent years, potent anti-hyperlipidemia drugs have been widely used, and the results of many intervention trials have shown that combinations of diet, exercise and drug therapies are effective for the primary and secondary prevention of coronary heart disease.
openaire   +3 more sources

Elevated Interleukin-38 Level Associates with Clinical Response to Atorvastatin in Patients with Hyperlipidemia

Cellular Physiology and Biochemistry, 2018
Background/Aims: Hyperlipidemia is a risk factor for various cardiovascular and metabolic disorders. And it is tightly related to chronic inflammation. Interleukin-38 (IL-38) represents a new member of anti-inflammatory cytokines.
Ning Yang, Yanqiu Song, Bo Dong, Yang Li, Lu Kou, Jingyu Yang, Qin Qin   +6 more
doaj   +1 more source

Alterations of Gut Microbiota and Blood Lipidome in Gestational Diabetes Mellitus With Hyperlipidemia

Frontiers in Physiology, 2019
Clinical gestational diabetes mellitus (GDM) is frequently associated with hyperlipidemia comorbidity. Altered human gut microbiome has been linked to GDM and hyperlipidemia, respectively but not the comorbid condition. We hypothesize that the occurrence
He Liu, He Liu, Li-Long Pan, Siting Lv, Qin Yang, Hao Zhang, Hao Zhang, Wei Chen, Wei Chen, Zhuwu Lv, Jia Sun, Jia Sun   +11 more
doaj   +1 more source

High dose simvastatin and adverse muscle effects

Universa Medicina, 2016
High blood cholesterol, or hyperlipidemia, is a cardiovascular risk factor. Surveys have demonstrated that 35.6% of adults in the United States suffer from hyperlipidemia.(1) Currently there are various therapeutic regimens available for hyperlipidemia ...
Yenny Yenny
doaj   +1 more source

Propolis supplementation can reduce serum level of interleukin-6, C-reactive protein, and tumor necrosis factor-α: an updated systematic review and dose-response meta-analysis on randomized clinical trials

Journal of Health, Population and Nutrition
Background New evidence suggested that propolis might reduce serum levels of inflammatory mediators; therefore, in this study we aimed to prove the potential effect of propolis on serum levels of interleukin-6 (IL-6), C-reactive protein (CRP), and tumor ...
Ali Gholami, Negar Dinarvand, Mitra Hariri   +2 more
doaj   +1 more source

Comparison of atherogenic indices for predicting the risk of metabolic syndrome in Southwest Iran: results from the Hoveyzeh Cohort Study (HCS)

Diabetology & Metabolic Syndrome
Background Metabolic syndrome (MetS) is a cluster of risk factors related to diabetes and cardiovascular disease (CVD). Given that early identification of MetS might decrease CVD risk, it is imperative to establish a simple and cost-effective method to ...
Hossein Babaahmadi‐Rezaei, Maedeh Raeisizadeh, Vahid Zarezade, Kourosh Noemani, Ahmad Mashkournia, Hossein Ghaderi-Zefrehi   +5 more
doaj   +1 more source

Association of urinary bisphenol A with hyperlipidemia and all-cause mortality: NHANES 2003-2016.

PLoS ONE
BackgroundThe connection between urinary bisphenol A (BPA) and hyperlipidemia is still unclear, and few studies have evaluated whether urinary BPA affects mortality among individuals with hyperlipidemia.
Lijuan Guo, Pin Zhao, Shilong Xue, Zhaowei Zhu   +3 more
doaj   +1 more source

Association between cooking patterns and the prevalence of hyperlipidemia in Eastern China

BMC Public Health
Background Hyperlipidemia is a major risk factor for many diseases. Previous studies have shown that diet is closely associated with hyperlipidemia. However, the relationship between cooking methods and hyperlipidemia remains unclear.
Bin Cui, Wen Kai Yuan, Linda Dong-Ling Wang, Fu Rong Wang, Jing Peng, Jian Ying Ma, Xiang Chen, Mei Yin Xu, Jun Ke, Yi Tian   +9 more
doaj   +1 more source

α-Ketoglutarate prevents hyperlipidemia-induced fatty liver mitochondrial dysfunction and oxidative stress by activating the AMPK-pgc-1α/Nrf2 pathway

Redox Biology
α-Ketoglutarate (AKG), a crucial intermediate in the tricarboxylic acid cycle, has been demonstrated to mitigate hyperlipidemia-induced dyslipidemia and endothelial damage.
Danyu Cheng, Mo Zhang, Yezi Zheng, Min Wang, Yilin Gao, Xudong Wang, Xuyun Liu, Weiqiang Lv, Xin Zeng, Konstantin N. Belosludtsev, Jiacan Su, Lin Zhao, Jiankang Liu   +12 more
doaj   +1 more source